[rac]-3-{2-Hydroxy-4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid | 475480-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: [rac]-3-{2-Hydroxy-4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid
• 英文别名: 3-[2-Hydroxy-4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-methoxypropanoic acid
• CAS: 475480-36-5
• 化学式: C₂₂H₂₃NO₆
• 分子量: 397.428
• InChiKey: LEZQUSKFURKRPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Oxazole derivatives
  申请人：——

  公开号：US20030055265A1

  公开（公告）日：2003-03-20

  The present invention relates to novel oxazole compounds which act as PPAR&agr; and PPAR&ggr; agonists and are accordingly useful for the treatment of diseases modulated by PPAR&agr; and PPAR&ggr; such as diabetes.

  本发明涉及新型噁唑化合物，其作为PPAR&agr;和PPAR&ggr;激动剂，并因此可用于治疗由PPAR&agr;和PPAR&ggr;调节的疾病，如糖尿病。
• [EN] CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS<br/>[FR] DERIVES D'ACIDE OXAZOLE-ARYLPROPIONIQUE CHIRAL ET LEUR UTILISATION EN TANT QU'AGONISTES DU RECEPTEUR PPAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004031162A1

  公开（公告）日：2004-04-15

  The present invention relates to compounds of Formula (I), wherein R1 to R6 and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment and/or prevention of diseases, which are modulated by PPARα and/or PPARϜ agonists as e.g. type II diabetes.

  本发明涉及式（I）的化合物，其中R1至R6和n如描述和索赔中所定义，并且其药学上可接受的盐和酯。这些化合物可用于治疗和/或预防由PPARα和/或PPARϜ激动剂调节的疾病，例如II型糖尿病。
• [EN] CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES<br/>[FR] DERIVES D'OXAZOLE SUBSTITUES PAR DE L'ACIDE CARBOXYLIQUE UTILES EN TANT QU'ACTIVATEURS PPAR-ALPHA ET GAMMA DANS LE TRAITEMENT DU DIABETE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002092084A1

  公开（公告）日：2002-11-21

  The present invention relates to compounds of formula (I) wherein R1 to R7 are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

  本发明涉及式(I)的化合物，其中R1至R7如描述和权利要求中所定义，并且其药学上可接受的盐和酯。该化合物可用于治疗糖尿病等疾病。
• Novel oxazole derivatives
  申请人：Binggeli Alfred

  公开号：US20050267180A1

  公开（公告）日：2005-12-01

  The present invention relates to compounds of formula (I) wherein wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and n are as described herein. The compounds of the present invention can be used as medicaments for the treatment and/or prevention of diseases which are modulated by PPARα and/or PPARγ agonists. Examples of such diseases are diabetes, particularly non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases, metabolic syndrome, endothelial dysfunction, procoagulant state, dyslipidemia, polycystic ovary syndrome, inflammatory diseases (such as e.g. crown disease, inflammatory bowel disease, collitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired/improvable cognitive function) and proliferative diseases.

  本发明涉及式(I)化合物，其中R1、R2、R3、R4、R5、R6和n如本文所述。本发明的化合物可用作治疗和/或预防由PPARα和/或PPARγ激动剂调节的疾病的药物。此类疾病的例子包括糖尿病，特别是非胰岛素依赖性糖尿病，高血压，升高的脂质和胆固醇水平，动脉粥样硬化疾病，代谢综合征，内皮功能障碍，促凝状态，脂质代谢异常，多囊卵巢综合征，炎症性疾病（例如克隆病、炎症性肠病、结肠炎、胰腺炎、肝胆疾病/纤维化以及具有炎症成分的疾病，例如阿尔茨海默病或受损/可改善的认知功能）和增生性疾病。
• CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1392295B1

  公开（公告）日：2006-05-31